ROCKET PHARMACEUTICALS, INC. (RCKT): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ROCKET PHARMACEUTICALS, INC. (RCKT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001281895 0001281895 2026-06-24 2026-06-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2026 R
How this was made
The 30-second read
Why it matters
The change affects the Principal Accounting Officer role and could influence investor perception of financial reporting continuity, but it does not include any new earnings, guidance, or operational metrics.
Market read
This is a governance/finance leadership transition disclosure with no stated financial impact, so it is unlikely to drive a major repricing by itself.
What to watch
The filing notes no new compensatory arrangements and no disclosed related-party transactions, which reduces the likelihood of immediate negative surprises.
Background
Rocket filed an SEC Form 8-K (Item 5.02) covering officer departure and appointment tied to finance/accounting leadership.
Ticker impact
Rocket Pharmaceuticals disclosed VP of Finance resignation effective July 7, 2026 and appointed Joseph Manhede as Principal Accounting Officer effective July 8, 2026.
Likely limited near-term impact; any reaction should be small unless investors view the change as a control-risk or succession issue.
The 8-K is a routine officer appointment/departure disclosure with no compensatory changes and no stated accounting-policy or restatement risk.
Market effects
Minimal; this is company-specific governance/finance staffing rather than a sector regulatory or clinical catalyst.
None indicated.
None indicated.
Counterpoint
Even without stated issues, a sudden VP of Finance resignation could reflect internal friction; traders may watch for follow-on filings (e.g., control weaknesses, restatements).
Key entities
- companyRocket Pharmaceuticals, Inc.
Nasdaq-listed biopharmaceutical company filing the 8-K for officer departure/appointment.
- executiveJohn Militello
Resigned as VP of Finance, Senior Controller, Treasurer, and Principal Accounting Officer effective July 7, 2026.
- executiveJoseph Manhede
Appointed Principal Accounting Officer effective July 8, 2026; previously Associate Vice President, Corporate Controller.
